Sponsors & Exhibitors
Commercial opportunities
If you are interested in exhibiting at, or sponsoring, this conference, please explore the commercial opportunities.
Choose from a variety of sponsorship and commercial options to raise your profile and position your company as a thought leader in the community.
Reasons why being a sponsor is a brilliant marketing strategy
Highly targeted marketing – reach your community
Brand awareness & recognition – logo and advertisement placement
Access to knowledge – find out about new research being undertaken
Engage with your audience – at the event and online
Media exposure - benefit from being promoted throughout Elsevier’s marketing process
Enhance credibility – highlight your company’s expertise to a captive audience
Generate new sales & form new partnerships – with registrants, vendors and speakers
Leveraged lead generation - the chance to be recommended to attendees’ connections
An exhibition will run alongside the conference sessions. Space is available on a first-come, first-served basis. In addition, a range of commercial sponsorship opportunities are available.
To discuss your requirements or to book sponsorship or exhibit space please contact: Ian Morley
Sales Executive, Conferences, Elsevier Email: [email protected] Mobile: +(44) 7747 541 955
OR
林韬
爱思唯尔（中国）期刊学术活动合作发展经理 邮箱: [email protected] 电话: +86 1381 0739 835
Exhibitors
KeAi
KeAi Communication Co., Ltd. (hereinaffer referred to as "KeAi") is a joint venture co-invested by China Science Publishing & Media Group Co., Ltd. (Science Press) and Elsevier—two world-leading publishing institutions in the fields of science, technology, and medicine (STM). Through years of efforts, it has grown into China's largest English-language academic journal publishing service provider.
With full support from Science Press and Elsevier, KeAi not only provides first-class technical support such as the premier dissemination platform ScienceDirect and the mainstream submission & peer review platform Editorial Manager, but also has built core capabilities in journal development strategy, disciplinary data analysis, domestic and international promotion, and database indexing application.
Currently, KeAi has a total of over 258 journals, among which:
• 32 are indexed in SCIE;
• 1 is indexed in AHCI;
• 73 are indexed in ESCI;
• 153 are indexed in Scopus (with 15 newly added in 2024 and 18 in 2025);
• 62 are indexed in EI (with 11 newly added in 2025);
Shanghai Clearvision Medical Technology Co., Ltd.
Shanghai Clearvision Medical Technology Co., Ltd. is located in Minhang District, Shanghai. With nucleic acid supramolecular hydrogel as its core technology, it devotes itself to the field of advanced biomaterials, focusing on technological R&D, achievement transformation and clinical translation and application. Its core product is the world's first nucleic acid supramolecular hydrogel. Relying on precise molecular design, excellent biocompatibility and mechanical properties, the company provides high-performance and customized biomaterial solutions for a variety of clinical scenarios such as stem cell therapy, tissue filling and repair, and ocular vitreous implantation, empowering the development of biomedicine and clinical medicine with innovative material technologies.
上海睛澈医疗科技有限公司位于上海闵行区，以核酸超分子水凝胶为核心技术，深耕新型生物材料领域，专注于技术研发、成果转化与临床落地应用。公司核心产品为全球首创的核酸超分子水凝胶，凭借精准分子设计、优异生物相容性与力学性能，为干细胞治疗、组织填充修复、眼玻璃体植入等多类临床场景，提供高性能、定制化的生物材料解决方案，以创新材料技术赋能生物医药与临床医疗发展。
